PT-141 (bremelanotide) is a melanocortin receptor agonist that was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is nicknamed the "Barbie peptide" because of its connection to Melanotan II, a tanning peptide, and its effects on both skin pigmentation and sexual arousal. PT-141 is particularly studied in women; see our PT-141 for women guide. PT-141 works through melanocortin pathways. Learn more in our Peptide Therapy: Complete Guide to Benefits, Types, and Safety [2026]. PT-141 (as Vyleesi) is FDA-approved, unlike many peptides affected by the FDA peptide ban. Some women combine PT-141 with the goddess stack peptide protocol.
Key Takeaway
PT-141 is the only FDA-approved on-demand medication for low sexual desire in women. It works through the central nervous system (melanocortin receptors in the brain), not through hormones or blood flow. Its most common side effect is nausea (40%). It is also used off-label in men for erectile dysfunction. For side effect context across medications, see our semaglutide side effects overview.
How Did PT-141 Go from a Tanning Peptide to a Sexual Health Drug?
The story starts at the University of Arizona in the 1980s. Researchers there were studying melanocortin peptides, specifically analogs of alpha-MSH (alpha-melanocyte-stimulating hormone), as potential sunless tanning agents. They synthesized a cyclic peptide called Melanotan II (MT-II) that reliably darkened skin by activating melanocortin-1 receptors (MC1R) on melanocytes [1].
During early human testing, a researcher self-administered a dose that was double the intended concentration. Within hours, he experienced severe nausea, vomiting, and an 8-hour erection. The tanning effect worked too, but the sexual side effect was impossible to ignore [1].
Melanotan II was too "dirty" pharmacologically, activating multiple melanocortin receptor subtypes with various side effects. So researchers modified the molecule to create PT-141 (bremelanotide), which shifted the receptor selectivity profile. PT-141 retains activity at MC3R and MC4R (the receptors linked to sexual arousal in the brain) while having reduced activity at MC1R (the tanning receptor). The structural change involved introducing a lactam bridge that altered the three-dimensional shape of the molecule [2].
Palatin Technologies developed PT-141 through clinical trials, and in June 2019, the FDA approved it as Vyleesi for HSDD in premenopausal women.
How Does PT-141 Work in the Brain?
PT-141 works through a completely different mechanism than other sexual health medications. Viagra and Cialis work on blood flow (PDE5 inhibitors targeting the vasculature). Testosterone therapy works through hormones. PT-141 works through the central nervous system [3].
View data table
| Category | Clinical Interest Score | Detail |
|---|---|---|
| BPC-157 | 88 | Tissue repair and gut healing |
| TB-500 | 82 | Injury recovery |
| Sermorelin | 78 | Growth hormone support |
| Ipamorelin | 75 | Anti-aging and recovery |
| GHK-Cu | 70 | Skin and tissue repair |
Specifically, PT-141 activates melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus and other brain regions involved in sexual arousal. These receptors are part of a signaling pathway that modulates desire, arousal, and sexual motivation at the neurological level. This is why PT-141 affects desire itself, not simply the physical mechanics of arousal [3].
The receptor binding order for bremelanotide is MC1R > MC4R > MC3R > MC5R > MC2R. The MC4R activation is believed to be the primary driver of its sexual effects, while residual MC1R activity explains why some users experience mild skin darkening at higher doses or with repeated use.
This CNS-based mechanism is what makes PT-141 unique. It is the only approved medication that targets sexual desire directly through brain signaling rather than through peripheral mechanisms like blood flow or hormone levels.
What Did the Clinical Trials Show?
The RECONNECT program, PT-141's phase 3 clinical program, comprised two identical randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women diagnosed with HSDD. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity [4].
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Both trials met their co-primary endpoints. Women receiving bremelanotide showed statistically significant improvements in sexual desire and statistically significant reductions in distress associated with low sexual desire compared to placebo (both p < 0.0001). The improvements were measured using validated scales: the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale (FSDS-DAO) [4].
Exit surveys from the RECONNECT studies showed that women treated with bremelanotide reported increased sexual desire, physical arousal, and improved quality of sexual activity and relationships [5].
A 52-week open-label extension study found no new safety signals during long-term use, and participants maintained improvements in HSDD symptoms throughout the treatment period [6].
What About PT-141 Use in Men?
PT-141 is FDA-approved only for premenopausal women with HSDD. It is not approved for men, postmenopausal women, or any other indication. That said, off-label use in men is common in clinical practice [7].
Phase 1 and phase 2 trials evaluated bremelanotide in men with erectile dysfunction. Subcutaneous doses of 1 to 6 mg and intranasal doses of 7 to 20 mg showed significant erectogenic effects in these studies. The mechanism is the same: CNS-mediated arousal through melanocortin receptor activation [7].
For men who do not respond to PDE5 inhibitors (Viagra, Cialis), PT-141 offers a different approach because it targets a different pathway entirely. A man who does not get results from blood flow-based medications may respond to a CNS-based approach. Some clinicians use both in combination, though this combination has limited formal study [7].
It is worth noting that PT-141 did not advance to FDA approval for men. Palatin Technologies chose to pursue the women's health indication, where the unmet need was more clearly defined (there were no approved on-demand medications for female sexual desire at the time).
What Is the Connection Between PT-141 and the "Barbie Peptide" Name?
The "Barbie peptide" nickname comes from the combination of effects associated with Melanotan II (PT-141's parent compound): tanning (a tan, "Barbie-like" appearance) and increased libido. In online communities and social media, Melanotan II became popular for its dual cosmetic and sexual effects, and the nickname transferred loosely to PT-141 [8].
The nickname is somewhat misleading for PT-141 specifically. Because PT-141 was engineered to reduce MC1R activation compared to Melanotan II, its tanning effects are much weaker. Some users report mild skin darkening with repeated PT-141 use, but it is not a reliable tanning agent. Melanotan II produces much more pronounced skin darkening because it has stronger MC1R activity.
The distinction between PT-141 and Melanotan II is important for safety reasons. Melanotan II is not FDA-approved for anything, has a broader side effect profile, and carries greater risk of atypical mole development and other dermatological concerns. PT-141 (as Vyleesi) is FDA-approved and has a defined safety profile from clinical trials. They are related molecules but not interchangeable.
What Are the Side Effects of PT-141?
Nausea is the dominant side effect, occurring in 40% of users in clinical trials. Other common side effects from the RECONNECT program include [4]:
- Flushing: 20.3%
- Injection site reactions: 13.2%
- Headache: 11.3%
- Vomiting: 4.8%
- Cough: 3.3%
- Fatigue: 3.2%
- Hot flashes: 2.7%
- Dizziness: 2.2%
- Nasal congestion: 2.1%
The nausea tends to be most pronounced with the first few doses and often diminishes with repeated use. Some clinicians recommend anti-nausea medication (ondansetron) for the first few uses. Taking PT-141 on an empty stomach may worsen nausea; a light meal beforehand can help.
PT-141 can cause transient increases in blood pressure. It should be used with caution in people with uncontrolled hypertension or cardiovascular disease. The FDA label recommends against use in patients with uncontrolled hypertension or known cardiovascular disease [9].
Skin hyperpigmentation (darkening) can occur, particularly in areas with existing pigmentation like the face, gums, and breast tissue. This is usually mild and reversible after discontinuation.
How Is PT-141 Dosed and Administered?
The FDA-approved dose of Vyleesi is 1.75 mg administered subcutaneously via an autoinjector pen, at least 45 minutes before anticipated sexual activity. The medication typically starts working within 30 to 60 minutes. The recommended limit is no more than one dose per 24 hours and no more than 8 doses per month [9].
In off-label use, dosing varies. Some clinicians start at lower doses (0.5 to 1 mg) to assess tolerance, particularly regarding nausea. Men are sometimes prescribed higher doses (up to 2 mg) based on earlier clinical trial data, though this is off-label [7].
PT-141 is administered as a subcutaneous injection, similar to insulin. The injection is typically given in the abdomen or thigh. It does not require refrigeration after reconstitution for short-term storage, though long-term storage should follow manufacturer guidelines.
peptide therapy programs through FormBlends can connect patients with providers who prescribe PT-141 and can guide proper dosing and administration.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, but only for one specific indication. Bremelanotide (brand name Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved for men, postmenopausal women, or any other condition. Off-label use in men does occur under physician supervision.
Does PT-141 work like Viagra?
No. PT-141 and Viagra work through completely different mechanisms. Viagra increases blood flow to the genitals by inhibiting PDE5. PT-141 activates melanocortin receptors in the brain to increase sexual desire and arousal at the neurological level. They target different parts of the arousal pathway.
Will PT-141 make my skin darker?
Mild skin darkening is possible, particularly with repeated use, because PT-141 retains some activity at MC1R (the melanocortin receptor responsible for skin pigmentation). The effect is much weaker than with Melanotan II. Any darkening is usually reversible after stopping use.
How quickly does PT-141 work?
PT-141 typically takes effect within 30 to 60 minutes after subcutaneous injection. The FDA label recommends administering it at least 45 minutes before anticipated sexual activity. Effects can last several hours.
Is PT-141 the same as Melanotan II?
No. PT-141 was derived from Melanotan II but has a different structure and receptor selectivity profile. PT-141 has reduced tanning effects and a more targeted mechanism for sexual function. Melanotan II is not FDA-approved and has a broader, less predictable side effect profile. They should not be considered interchangeable.
Can men use PT-141?
PT-141 is not FDA-approved for men, but off-label use is common. Clinical trials in men showed erectogenic effects at subcutaneous doses of 1 to 6 mg. It may be an option for men who do not respond to PDE5 inhibitors, as it works through a different mechanism. Use should be supervised by a licensed provider.
How often can I use PT-141?
The FDA label recommends no more than one dose per 24 hours and no more than 8 doses per month. It is designed for on-demand use before sexual activity, not daily use. Exceeding recommended frequency may increase the risk of side effects, particularly nausea and blood pressure elevation.
Why is PT-141 called the Barbie peptide?
The nickname comes from its parent compound Melanotan II, which was popular in online communities for its combination of tanning and libido effects. The "Barbie" reference links the tan skin and increased sexual desire. The name is more applicable to Melanotan II than to PT-141, which has much weaker tanning activity.
Medical References
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534
- Wikberg JE, Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat Rev Drug Discov. 2008;7(4):307-323.
- Kingsberg SA, et al. Melanocortin Receptors, Melanotropic Peptides and Penile Erection. Curr Top Med Chem. 2007;7(11):1098-1106. PMC2694735
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840
- Koochaki PE, et al. Bremelanotide and Hypoactive Sexual Desire Disorder: patient perspectives from the RECONNECT exit study. J Sex Med. 2021;18(1):191-200.
- Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMC6819023
- Gilbert BR. PT-141 for Men: A New Drug to Treat Erectile Dysfunction and Low Libido. MensReproductiveHealth.com. Accessed April 2026.
- Swolverine. Melanotan II & PT-141 for Women: Tanning, Libido, and Risks. Swolverine.com. Accessed April 2026.
- FDA. VYLEESI (bremelanotide injection) Prescribing Information. U.S. Food and Drug Administration. 2019. FDA Label
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any medication or protocol. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10